IMP3 Expression in Borderline Tumors of the Ovary.
Anticancer Res
; 37(2): 583-588, 2017 02.
Article
em En
| MEDLINE
| ID: mdl-28179304
ABSTRACT
BACKGROUND/AIM:
Borderline ovarian tumors (BOTs) have a less aggressive behavior than invasive epithelial ovarian tumors. Still some patients relapse or succumb to disease. Molecular markers that reliably predict prognosis are lacking. Insulin-like growth factor II mRNA-binding protein (IMP3) has been suggested as a prognostic marker in colorectal, hepatocellular, and ovarian clear-cell carcinomas. MATERIALS ANDMETHODS:
We analyzed the expression of IMP3 by immunohistochemistry in a cohort of 140 BOT and its association with histopathological features.RESULTS:
We found no association of IMP3 expression with patients' age, FIGO stage, microinvasion, and presence of implants. In contrast, IMP3 expression correlated to mucinous subtype of BOTs (42.2% vs. 9.5% among other subtypes) (p<0.001). IMP3 expression was found to be associated with the presence of in situ carcinoma in MBOT, but not in other subtypes (p=0.021).CONCLUSION:
Expression of IMP3 in BOT is associated with the mucinous subtype and may serve as an early indicator for the development of malignant features.Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Biomarcadores Tumorais
/
Proteínas de Ligação a RNA
/
Neoplasias Epiteliais e Glandulares
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article